$1.67
+0.07 (+4.38%)
Open$1.61
Previous Close$1.60
Day High$1.71
Day Low$1.61
52W High$41.09
52W Low$27.16
Volume—
Avg Volume131.9K
Market Cap52.70M
P/E Ratio17.43
EPS$1.84
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+2,451.5% upside
Current
$1.67
$1.67
Target
$42.61
$42.61
$22.54
$42.61 avg
$49.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 27.49M | 26.17M | 29.17M |
| Net Income | -6,413,122 | -6,638,758 | -7,979,028 |
| Profit Margin | -23.3% | -25.4% | -27.4% |
| EBITDA | -10,041,478 | -10,799,684 | -11,152,703 |
| Free Cash Flow | -6,132,912 | -6,792,749 | -5,207,622 |
| Rev Growth | +12.4% | +6.3% | +17.3% |
| Debt/Equity | 0.29 | 0.25 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |